Abstract
The aims of this study were to validate and compare HPLC and LCMSMS analytical methods and their applicability for the quantitation of imatinib in human plasma. A total of 50 patients with chronic myeloid leukemia (CML) in chronic phase (CP) receiving 400 mg/day imatinib were enrolled in the study. Drug levels were determined by HPLC-UV and LCMSMS. HPLC intra-day accuracy ranged from 100.51 to 103.19%. LCMSMS accuracy ranged from 89.72 to 106.29%. The correlation coefficient between both methods was r(2)=0.96. HPLC can be used for imatinib levels' determinations in patients accurately and precisely.
Copyright 2009 Elsevier Ltd. All rights reserved.
Publication types
-
Comparative Study
-
Validation Study
MeSH terms
-
Adult
-
Antineoplastic Agents / analysis
-
Antineoplastic Agents / blood
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Blood Chemical Analysis / methods*
-
Blood Chemical Analysis / standards
-
Calibration
-
Chromatography, High Pressure Liquid / methods
-
Chromatography, High Pressure Liquid / standards
-
Chromatography, Liquid / methods
-
Chromatography, Liquid / standards
-
Circadian Rhythm / physiology
-
Female
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Male
-
Middle Aged
-
Piperazines / analysis*
-
Piperazines / blood
-
Piperazines / therapeutic use
-
Protein Kinase Inhibitors / analysis
-
Protein Kinase Inhibitors / blood
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrimidines / analysis*
-
Pyrimidines / blood
-
Pyrimidines / therapeutic use
-
Randomized Controlled Trials as Topic
-
Sensitivity and Specificity
-
Spectrophotometry, Ultraviolet / methods
-
Spectrophotometry, Ultraviolet / standards
-
Tandem Mass Spectrometry / methods*
-
Tandem Mass Spectrometry / standards
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Imatinib Mesylate